Aclarion Announces Takes Big Step with Initial Scripps Health Commercial Agreement

March 3, 2025

DENVER, Colo., Mar 03, 2025 (247marketnews.com)- Aclarion (NASDAQ:ACON) took a significant step forward in its mission to transform how chronic low back pain (cLBP) is diagnosed and treated. The healthcare technology company announced its first commercial agreement with Scripps Health, a leading nonprofit healthcare system in San Diego, California. This partnership not only brings Aclarion’s pioneering Nociscan technology to Southern California but also positions the company as a serious contender in the fight against one of the world’s most pervasive and costly health challenges.

Robert Eastlack, MD, Orthopedic Surgeon, Scripps Health, commented, “Each year at Scripps, we evaluate a large, growing number of patients suffering from chronic low back pain. I have a keen interest in advanced diagnostics and clinical decision support tools like Nociscan. Over the last few years, I have referred numerous patients to Beverly Hills for Nociscan. The additional information unique from Nociscan has been valuable to me and my patients. Having Nociscan available at Scripps Green will greatly expand access to my colleagues and our patients in important ways.”

The agreement with Scripps Health could become a game-changer for Aclarion and the 3.2 million residents of the greater San Diego metro area. Scripps Health, the region’s largest healthcare network, boasts five hospitals, 19 outpatient facilities, and a team of 2,600 affiliated physicians who treat half a million patients annually. Renowned for its commitment to clinical research and medical education, Scripps is an ideal partner to showcase Nociscan—a cutting-edge diagnostic tool that promises to redefine spine care.

“Dr. Eastlack is a leader within Scripps, as well as the San Diego Spine Foundation and the International Spine Study Group, having published over 100 peer-reviewed articles and contributing to nearly a dozen textbooks,” said Ryan Bond, Chief Strategy Officer of Aclarion. “We are pleased to bring Nociscan to Scripps Health and the millions of people throughout Southern California. Dr. Eastlack and his colleagues will now be able to utilize Nociscan in clinic and within on-going research trials, both of which are vitally important to their mission of advancing spine care.”

For the leading spine physicians at Scripps Green and throughout the system, Nociscan offers a new lens through which to tackle chronic low back pain. By integrating this technology into their practice, these specialists gain access to a tool that complements their expertise with precise, data-driven insights. This collaboration is meant to be a proof of concept that could pave the way for Aclarion’s expansion across the U.S. and beyond.

cLBP affects approximately 266 million people globally.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (ACON)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.